Let's Learn About the Digital Manufacturing in Life Sciences Market Companies with Key Development
- Siemens AG
- Dassault Systèmes
- Rockwell Automation
- Honeywell International
- GE Vernova/GE Digital
- ABB Ltd.
- AspenTech
- Schneider Electric
- AVEVA Group
- SAP SE
- Veeva Systems
- IBM Corporation
- Emerson Electric Co.
- POMSnet (Werum IT Solutions)
- Thermo Fisher Scientific
- Lonza Group AG
- Catalent, Inc.
- Samsung Biologics
- Cytiva (Danaher)
- Amazon Web Services (AWS) Healthcare & Life Science
What does Digital Manufacturing in Life Science Mean?
Digital manufacturing in life sciences integrates advanced technologies such as automation, artificial intelligence (AI), machine learning (ML), Internet of Things (IoT), digital twins, and cloud computing into pharmaceutical and biotechnology production processes. It aims to streamline operations across R&D, process development, and large-scale manufacturing while ensuring compliance with Good Manufacturing Practices (GMP). Through predictive analytics, real-time monitoring, and process optimization, digital manufacturing improves productivity, product quality, and time-to-market. It is pivotal for biologics, cell & gene therapies, vaccines, and personalized medicines, enabling smart, flexible, and data-driven manufacturing ecosystems.
Market Growth
The global digital manufacturing in life sciences market size is calculated at US$ 41.65 billion in 2025, grew to US$ 48.15 billion in 2026, and is projected to reach around US$ 177.5 billion by 2035. The market is expected to expand at a CAGR of 15.6% between 2026 and 2035.
Market Outlook
- Industry Growth Overview: The digital manufacturing in life sciences market sciences is growing rapidly due to the widespread use of automation and artificial intelligence in production. Growing R&D expenditures, as well as the pressing need for quicker, more effective drug discovery and development procedures, are driving this expansion.
- Global Expansion: North America is still the market leader, but the Asia-Pacific area is expanding at the fastest rate because of the quick industrial digitalization and encouraging government policies in nations like China and India. These areas are updating their operations to satisfy demand from around the world.
- Startup Ecosystem: Numerous health-tech and life sciences startups are emerging worldwide, making the startup ecosystem of digital manufacturing in life sciences market a shining example of innovation. A dynamic environment for future innovations is being created by government support and private investment, which are encouraging advancements in AI-driven solutions and personalized medicine.
Company Landscape
Siemens AG
Company Overview
Siemens AG: A global industrial technology company that provides automation, digitalization, and digital manufacturing solutions across industries, including life sciences.
Corporate Information
- Headquarters: Munich, Germany
- Year Founded: 1847 (as Siemens & Halske)
- Ownership Type: Public company (listed on German and other exchanges)
History and Background
- Originally an electrical telegraph and engineering business; over time, diversified into transport, energy, automation, and digital industries.
- Digital Industries division (covering automation, software, industrial IoT) has grown significantly in recent years.
- In 2022 launched the Siemens Xcelerator platform – a digital business platform for industrial software, hardware, and services.
Key Milestones/Timeline
- June 2023: Aiming to raise the software business’s sales share to ~20 %.
- November 4, 2025: Announced expanded strategic partnership with Capgemini to build AI-native digital manufacturing solutions for life sciences and other industries.
- April 2, 2025: Announced acquisition of Dotmatics (US R&D software company) for ~$5.1 billion to bolster life-sciences software/PLM capabilities.
Business Overview
- Business Segments/Divisions
- Digital Industries (software, automation, industrial IoT)
- Smart Infrastructure, Mobility, Energy, Healthcare & Life Sciences (via subsidiaries)
- Dedicated segment addressing Life Sciences & Health Technology through tailored solutions
Geographic Presence
- Global operations across Europe, North America, Asia-Pacific, Latin America, the Middle East & Africa
- Strong presence in manufacturing hubs globally
Key Offerings
- Digital manufacturing software (PLM, MES, digital twin, simulation)
- Automation hardware & systems (controllers, drives, sensors) for manufacturing lines
- Industry-specific solutions for life sciences (pharma/biotech manufacturing, med-tech)
End-Use Industries Served
- Life sciences & pharmaceuticals (manufacturing, critical environments)
- Medtech / medical devices
- Automotive, aerospace, heavy equipment
- Electronics, consumer goods
Key Developments and Strategic Initiatives
- Mergers & Acquisitions
- Acquisition of Dotmatics (Apr 2025) to expand life-sciences software footprint
- Earlier acquisition of engineering software firm Altair for ~$10.6 billion
- Partnerships & Collaborations
- Partnership with Capgemini (Nov 2025) on AI-native manufacturing solutions in life sciences
- Collaborations with NVIDIA, Microsoft, AWS for industrial AI and digital twin capabilities
- Product Launches/Innovations
- Siemens Xcelerator platform (industrial digital platform)
- Digital manufacturing solutions integrating simulation, 3D visualization, analytics, and collaboration tools
- Capacity Expansions/Investments
- Investment in expanding digital software and services offerings globally; specific capacities in manufacturing lines for life sciences noted in case studies
- Regulatory Approvals
- Compliant with global manufacturing standards and data security regulations; life sciences solutions support compliance in pharma manufacturing
- Distribution Channel Strategy
- Global partner ecosystem (system integrators, software resellers, automation equipment suppliers)
- Direct sales of software & hardware plus services, consulting, and support
- Platform approach via Siemens Xcelerator, enabling subscription/SaaS models
- Technological Capabilities / R&D Focus
- Core Technologies/Patents
- Digital twin, industrial IoT, simulation, PLM, MES, automation hardware & software stack
- Proprietary tools, including Siemens NX, Tecnomatix, Opcenter
- Research & Development Infrastructure
- Global R&D centers; investment in industrial digitalization and life-sciences manufacturing transformation Continuous
- innovation in digital twin, AI/ML for manufacturing, simulation, and advanced automation
- Innovation Focus Areas
- AI-native manufacturing tools for life sciences (e.g., generative AI in MES workflows)
- Digital twin for pharma/biotech production lines and critical environments
- End-to-end integration of product/process design and manufacturing for speed, flexibility, and quality
Competitive Positioning
- Strengths & Differentiators
- Global scale, deep technology stack across hardware, software, and services
- Strong in digital manufacturing across industries, now applying to life sciences
- Platform offering (Siemens Xcelerator) allows integrated solutions
- Strategic acquisitions (e.g., Dotmatics) strengthen life-sciences-oriented software
- Recognized leader in industrial digitalization
- Market Presence & Ecosystem Role
- Key enabler of “Pharma 4.0” / life-sciences manufacturing digital transformation
- Works with pharma/biotech and med-tech companies to implement digital manufacturing and automation solutions
SWOT Analysis
- Strengths: Comprehensive offering, global scale, strong brand, cross-industry experience
- Weaknesses: Complex offerings may slow time-to-value; integration across business units can be challenging
- Opportunities: Growth in life-sciences manufacturing digitalization, pharma/biotech automation, digital twin, and AI adoption
- Threats: Competition from specialized software/automation vendors; regulatory/environmental shifts; economic disruptions
Recent News and Updates
- Press Releases
- Siemens & Capgemini collaboration announcement (Nov 2025) on AI-native solutions for manufacturing, including life sciences
- Acquisition of Dotmatics (Apr 2025) to bolster life-sciences portfolio
- Industry Recognitions/Awards
- Siemens Digital Industries Software recognized for market vision and product capabilities
Thermo Fisher Scientific Inc.
Company Overview
Thermo Fisher Scientific: A leading global provider of laboratory instruments, analytical equipment, reagents, consumables, software, and services to the life-sciences, biopharma, diagnostics, and manufacturing sectors—including digital manufacturing support for life-sciences production.
Corporate Information
- Headquarters: Waltham, Massachusetts, U.S.
- Year Founded: 1956 (via merger of Thermo Electron and Fisher Scientific in 2006)
- Ownership Type: Public company listed on U.S. exchanges
History and Background
- Thermo Electron founded in 1956; Fisher Scientific founded earlier; merged in 2006 to form Thermo Fisher Scientific
- Expanded via acquisitions into analytical instruments, life-sciences consumables, services, software, and manufacturing support for biotech/pharma
Key Milestones/Timeline
- 2013: Acquisition of Life Technologies Corporation
- 2016: Acquisition of Affymetrix and FEI Company
- 2018: Acquisition of BD Advanced Bioprocessing
- 2021: Acquisition of PPD (clinical research services)
- 2025: Announced a $2 billion investment (over four years) in U.S.-based biotech manufacturing capacity and R&D investment
- 2025 (Oct): Plan to acquire Clario (clinical services/data management) for ~$9.4 billion as part of digital health and manufacturing expansion
Business Overview
- Business Segments/Divisions
- Life Sciences Solutions (instruments, consumables, software)
- Analytical Instruments
- Specialty Diagnostics
- Laboratory Products & Services
- Manufacturing & Bioprocessing solutions for pharma/biotech
Geographic Presence
- Global footprint across the Americas, Europe, Asia-Pacific, Middle East & Africa
- Manufacturing and operational sites in major biotech hubs
Key Offerings
- Instruments: chromatography, mass spectrometry, spectroscopy, sequencers
- Consumables: reagents, labware, kits
- Software & services: lab management, digital automation, manufacturing technologies
- Bioprocessing & manufacturing solutions for pharma/biotech
- Digital manufacturing/automation support for life sciences production
End-Use Industries Served
- Pharmaceuticals & Biotech (R&D, manufacturing)
- Diagnostics & Clinical labs
- Academic & Government research labs
- Industrial & applied markets
- Contract manufacturing/biotech manufacturing support
Key Developments and Strategic Initiatives
- Mergers & Acquisitions
- Acquisitions of Life Technologies, Affymetrix, FEI, BD Advanced Bioprocessing, and PPD
- 2025: Plan to acquire Clario for ~$9.4 billion to strengthen digital health/data/clinical trial services
- Partnerships & Collaborations
- Collaborates with major pharma & biotech companies for digital manufacturing and data solutions
- Product Launches/Innovations
- Expanded digital instrument and lab workflow tools
- 2025: $2 billion investment in manufacturing capacity and R&D aimed at scaling biotech production
- Capacity Expansions/Investments
$2 billion U.S. investment over four years, including $1.5 billion for manufacturing and $500 million for R&D
Regulatory Approvals
- Operates under strict compliance for manufacturing support in regulated life sciences environments
- Distribution Channel Strategy
- Direct global sales of instruments, consumables, and services
- Partner network and authorized distributors
- Digital/online platforms for software and support
- Technological Capabilities / R&D Focus
Core Technologies/Patents
- Analytical instrumentation, high-throughput lab systems, automation, and manufacturing technologies
- Software for lab informatics, digital manufacturing, and data management
Research & Development Infrastructure
Global R&D centers focusing on biotechnology manufacturing and digital technologies
Innovation Focus Areas
- Bioprocessing/manufacturing for biotech
- Digital manufacturing/automation in life sciences production
- Data management and software for lab and biopharma workflows
Competitive Positioning
- Strengths & Differentiators
- Market leader in life sciences instruments and consumables
- Extensive manufacturing support for biopharma/biotech
- Strong acquisition strategy enhancing digital capabilities
- Trusted brand with global presence in regulated industries
- Market Presence & Ecosystem Role
- Key supplier to pharmaceutical and biotech manufacturing ecosystems
- Enabler of digital manufacturing in life sciences, integrating hardware and software
- Operates across lab instrumentation, manufacturing, and automation ecosystems
SWOT Analysis
- Strengths: Scale, broad portfolio, manufacturing support, global reach
- Weaknesses: High capital intensity, margin pressure, competition from digital-native players
- Opportunities: Growth in biotech manufacturing, digitalization of life-sciences production, and outsourcing trends
- Threats: Digital disruption, regulatory challenges, macroeconomic headwinds
Recent News and Updates
- Press Releases
- 2025: $2 billion investment in U.S. manufacturing and R&D
- Oct 2025: Planned acquisition of Clario for $9.4 billion to expand digital health capabilities
- Industry Recognitions/Awards
- Consistently ranked among the top global life-sciences firms and Fortune 500 companies
- Reported revenue of approximately $42.879 billion in 2024
Recent Developments in the Market
- In April 2025, through its Digital Membership consortium, CPI has partnered with leading global digital pharmaceutical companies such as AstraZeneca, Atos, AWS, Capgemini, GSK, and Siemens to introduce a groundbreaking Digital Architecture that will transform the pharmaceutical manufacturing process.
- In January 2025, through digital transformation and sophisticated automation, Honeywell unveiled the TrackWise® Life Sciences Platform, a solution specifically created to transform how life sciences organizations approach integrated manufacturing and quality management.
Collaborate with our experts to explore the Digital Manufacturing in Life Sciences Market at sales@towardshealthcare.com
